262 related articles for article (PubMed ID: 20055981)
1. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.
Bafaloukos D; Linardou H; Aravantinos G; Papadimitriou C; Bamias A; Fountzilas G; Kalofonos HP; Kosmidis P; Timotheadou E; Makatsoris T; Samantas E; Briasoulis E; Christodoulou C; Papakostas P; Pectasides D; Dimopoulos AM
BMC Med; 2010 Jan; 8():3. PubMed ID: 20055981
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Mahner S; Meier W; du Bois A; Brown C; Lorusso D; Dell'Anna T; Cretin J; Havsteen H; Bessette P; Zeimet AG; Vergote I; Vasey P; Pujade-Lauraine E; Gladieff L; Ferrero A
Eur J Cancer; 2015 Feb; 51(3):352-8. PubMed ID: 25534295
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Gladieff L; Ferrero A; De Rauglaudre G; Brown C; Vasey P; Reinthaller A; Pujade-Lauraine E; Reed N; Lorusso D; Siena S; Helland H; Elit L; Mahner S
Ann Oncol; 2012 May; 23(5):1185-1189. PubMed ID: 21976386
[TBL] [Abstract][Full Text] [Related]
4. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.
Pignata S; Scambia G; Savarese A; Breda E; Scollo P; De Vivo R; Rossi E; Gebbia V; Natale D; Del Gaizo F; Naglieri E; Ferro A; Musso P; D'Arco AM; Sorio R; Pisano C; Di Maio M; Signoriello G; Annunziata A; Perrone F;
BMC Cancer; 2006 Aug; 6():202. PubMed ID: 16882344
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
Alberts DS; Liu PY; Wilczynski SP; Clouser MC; Lopez AM; Michelin DP; Lanzotti VJ; Markman M;
Gynecol Oncol; 2008 Jan; 108(1):90-4. PubMed ID: 17949799
[TBL] [Abstract][Full Text] [Related]
8. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
9. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
[TBL] [Abstract][Full Text] [Related]
10. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
11. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
[TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
Kurtz JE; Kaminsky MC; Floquet A; Veillard AS; Kimmig R; Dorum A; Elit L; Buck M; Petru E; Reed N; Scambia G; Varsellona N; Brown C; Pujade-Lauraine E;
Ann Oncol; 2011 Nov; 22(11):2417-2423. PubMed ID: 21402619
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
Power P; Stuart G; Oza A; Provencher D; Bentley JR; Miller WH; Pouliot JF
Gynecol Oncol; 2009 Sep; 114(3):410-4. PubMed ID: 19520420
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
15. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.
Wagner U; Marth C; Largillier R; Kaern J; Brown C; Heywood M; Bonaventura T; Vergote I; Piccirillo MC; Fossati R; Gebski V; Lauraine EP
Br J Cancer; 2012 Aug; 107(4):588-91. PubMed ID: 22836511
[TBL] [Abstract][Full Text] [Related]
16. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
17. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
Joly F; Ray-Coquard I; Fabbro M; Donoghoe M; Boman K; Sugimoto A; Vaughan M; Reinthaller A; Vergote I; Ferrandina G; Dell'Anna T; Huober J; Pujade-Lauraine E
Gynecol Oncol; 2011 Aug; 122(2):226-32. PubMed ID: 21575983
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer.
Rapoport BL; Vorobiof DA; Slabber C; Alberts AS; Hlophe HS; Mohammed C
Int J Gynecol Cancer; 2009 Aug; 19(6):1137-41. PubMed ID: 19820382
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
Pectasides D; Pectasides E; Papaxoinis G; Psyrri A; Pliarchopoulou K; Koumarianou A; Macheras A; Athanasas G; Xiros N; Economopoulos T
Gynecol Oncol; 2010 Jul; 118(1):52-7. PubMed ID: 20406710
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
Pignata S; Scambia G; Ferrandina G; Savarese A; Sorio R; Breda E; Gebbia V; Musso P; Frigerio L; Del Medico P; Lombardi AV; Febbraro A; Scollo P; Ferro A; Tamberi S; Brandes A; Ravaioli A; Valerio MR; Aitini E; Natale D; Scaltriti L; Greggi S; Pisano C; Lorusso D; Salutari V; Legge F; Di Maio M; Morabito A; Gallo C; Perrone F
J Clin Oncol; 2011 Sep; 29(27):3628-35. PubMed ID: 21844495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
